Copyright
©The Author(s) 2024.
World J Clin Oncol. Apr 24, 2024; 15(4): 540-547
Published online Apr 24, 2024. doi: 10.5306/wjco.v15.i4.540
Published online Apr 24, 2024. doi: 10.5306/wjco.v15.i4.540
Table 4 Comparative analysis of survival analysis by KRAS status
| Survival analysis | KRAS wild type | KRAS mutated type | ||
| Immunotherapy vs chemotherapy | Hazard ratio (95%CI) | Adjusted hazard ratio (95%CI) | Hazard ratio (95%CI) | Adjusted hazard ratio (95%CI) |
| Overall | 1.16 (0.86-1.56) | 1.01 (0.75-1.37) | 0.67 (0.42-1.07) | 0.70 (0.44-1.12) |
| One year | 1.28 (0.88-1.87) | 1.14 (0.78-1.68) | 1.33 (0.71-2.49) | 1.33 (0.71-2.50) |
| Three year | 1.17 (0.87-1.58) | 1.02 (0.76-1.37) | 0.66 (0.41-1.07) | 0.68 (0.42-1.09) |
- Citation: Niu CG, Zhang J, Rao AV, Joshi U, Okolo P. Comparative effectiveness of immunotherapy and chemotherapy in patients with metastatic colorectal cancer stratified by microsatellite instability status. World J Clin Oncol 2024; 15(4): 540-547
- URL: https://www.wjgnet.com/2218-4333/full/v15/i4/540.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i4.540